TNF.alpha. receptor-derived binding protein
AssigneeThe Mathilda and Terence Kennedy Institute of Rheumatology
InventorsMarc Feldmann, Patrick W. Gray, Martin J. C. Turner, Fionula M. Brennan
Life of this patent
Estimating the term…
Abstract
A polypeptide is provided which is capable of binding human TNF.alpha. and which has the first three cysteine-rich subdomains, but not the fourth cysteine-rich subdomain, of the extracellular binding domain of a receptor selected from the group consisting of the 55 kD and 75 kD receptors for human TNF.alpha.. The ability of the polypeptide to bind TNF.alpha. means that it can be used for treating diseases mediated by TNF.alpha. activity, such as rheumatoid arthritis.
Claims9
A polypeptide which is capable of binding human TNF.alpha. and which has the first three cysteine-rich subdomains, but not the fourth cysteine-rich subdomain, of the extracellular binding domain of a receptor selected from the group consisting of the 55 kD and 75 kD receptors for human TNF.alpha..
A process for the preparation of a polypeptide which is capable of binding human TNF.alpha. and which has the first three cysteine-rich subdomains but not the fourth cysteine-rich subdomain of the extracellular binding domain of a receptor selected from the group consisting of the 55 kD and 75 kD receptors for human TNF.alpha., which process comprises
- (i) culturing a host transformed with a vector encoding said polypeptide under such conditions that said polypeptide is expressed;
- and
- (ii) isolating said polypeptide.
A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and, as an active principle, a polypeptide which is capable of binding human TNF.alpha. and which has the first three cysteine-rich subdomains, but not the fourth cysteine-rich subdomain, of the extracellular binding domain of a receptor selected from the group consisting of the 55 kD and 75 kD receptors for human TNF.alpha..
Dependencies are inferred from the claim text.